Omeros and Keryx are Potential Beneficiaries of New Administration Deregulation

NEW YORK, NY / ACCESSWIRE / March 21, 2017 / The current word from market observers is that the biotech sector may have new life breathed into it by a Republican led Congress and the new administration. New reforms regarding the holding of significant cash reserves by major pharmaceutical companies may allow that cash back into the company’s coffers, opening the door for increased acquisition activity in the sector. Also, there may be possible new FDA regulations regarding the expedition in the approval process of new drugs, allowing more new drugs, and profits, into the market.

RDI Initiates
Coverage:

Omeros Corporation https://ub.rdinvesting.com/news/?ticker=OMER

Keryx
Biopharmaceuticals https://ub.rdinvesting.com/news/?ticker=KERX

Omerus spiked up $1.54 from Friday’s close to end Monday at a price of $11.75 a share. The rise in price was questioned by some investors who noted the significant amount of insider trading of selling in the 4th quarter of 2016. The company develops and seeks to commercialize therapies that target inflammation, coagulopathies, and disorders of the central nervous system. The stock is up almost 18.5 percent for the year-to-date, and its lead candidate therapy, OMS721, is said to have some promise as the Phase-2 clinical trial of the drug was heralded as a success. Omeros has reported a loss of $66.75 million or $1.65 a share for the year of 2016, as against loss of $75.1 million or $2.00 a share reported in the year 2015. While revenue increased significantly to $41.6 million in the year 2016 up from $13.5 million of reported revenue in 2015, the company had $45.3 million of Cash, cash equivalents and short term investments as on December 31, 2016.

Access RDI’s Omeros Corporation Research Report at: https://ub.rdinvesting.com/news/?ticker=OMER

If you are an investor in a biotech company, and one of its drugs is approved to be placed on the formulary of one of the largest Part D Medicare Plans sponsors, you can start to give yourself credit for such excellent investing judgment. Such is the case for Keryx, whose stock shot up 46 cents to close at $6.29 per share on Monday. The drug, Auryxia(R), has been approved for immediate use and is used in the treatment for people for the control of serum phosphorus levels who are on end-stage type of renal disease. Keryx, with its recent sNDA submission on March 8th, is seeking to expand to include the treatment of iron deficiency anemia (IDA) in patients with non-dialysis dependent chronic kidney disease (NDD-CKD).

Access RDI’s Keryx Biopharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=KERX

Our Actionable Research on Omeros Corporation (NASDAQ: OMER) and Keryx Biopharmaceuticals (NASDAQ: KERX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457816